硫酸镁联合拉贝洛尔对重度子痫前期患者凝血功能、氧化应激及血管内皮功能的影响

摘要 目的：探讨硫酸镁联合拉贝洛尔对重度子痫前期患者凝血功能、氧化应激及血管内皮功能的影响。方法：选择2020年1月~2022年9月期间来安徽医科大学附属巢湖医院就诊的重度子痫前期患者94例。采用随机数字表法将患者分为对照组（硫酸镁治疗，47例）和研究组（硫酸镁联合拉贝洛尔治疗，47例）。两组均于治疗前后观察收缩压（SBP）、舒张压（DBP）、24 h尿蛋白量（24hUP）、凝血功能、氧化应激及血管内皮功能的变化情况，同时观察两组用药安全性。结果：治疗后，研究组SBP、DBP、24hUP低于对照组（P<0.05）。治疗后，研究组内皮素-1（ET-1）低于对照组，一氧化氮（NO）高于对照组（P<0.05）。治疗后，研究组丙二醛（MDA）低于对照组，超氧化物歧化酶（SOD）高于对照组（P<0.05）。治疗后，研究组纤维蛋白原（Fg）、D-二聚体（D-D）低于对照组，凝血酶原时间（PT）、凝血活酶时间（APTT）高于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：拉贝洛尔联合硫酸镁治疗重度子痫前期患者，可减少24hUP，有效降低血压，改善凝血功能和血管内皮功能，减轻氧化应激损伤。

Effects of Magnesium Sulfate Combined with Labetalol on Coagulation Function, Oxidative Stress and Vascular Endothelial Function in Patients with Severe Preeclampsia

ABSTRACT Objective: To investigate the effects of magnesium sulfate combined with labetalol on coagulation function, oxidative stress and vascular endothelial function in patients with severe preeclampsia. Methods: 94 patients with severe preeclampsia who came to Chaohu Hospital affiliated to Anhui Medical University from January 2020 to September 2022 were selected. The patients were randomly divided into control group (magnesium sulfate treatment, 47 cases) and study group (magnesium sulfate combined with labetalol treatment, 47 cases) by random number table method. Before and after treatment, the changes of systolic blood pressure (SBP), diastolic blood pressure(DBP), 24 h urine protein volume (24hUP), coagulation function, oxidative stress and vascular endothelial function indexes were observed in two groups, and the drug safety in the two groups was observed. Results: After treatment, SBP, DBP and 24hUP in the study group were lower than those in the control group (P<0.05). After treatment, endothelin-1 (ET-1) in the study group was lower than that in the control group, while nitric oxide (NO) was higher than that in the control group (P<0.05). After treatment, malondialdehyde (MDA) in the study group was lower than that in the control group, and superoxide dismutase(SOD) in the study group was higher than that in the control group (P<0.05). After treatment, the fibrinogen (Fg) and D-dimer (D-D) in the study group were lower than those in the control group, and the prothrombin time (PT) and thrombin time (APTT) in the study group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions in the two groups(P>0.05). Conclusion: Labelolol combined with magnesium sulfate in the treatment of patients with severe preeclampsia can reduce 24hUP, effectively reduce blood pressure, improve coagulation function and vascular endothelial function, and alleviate oxidative stress damage.